Video

Dr. Heimbach on Liver Transplant Criteria in HCC

Julie K. Heimbach, MD, discusses the criteria for liver transplantation in patients with hepatocellular carcinoma.

Julie K. Heimbach, MD, a transplant surgeon and the surgical director of Liver Transplantation at Mayo Clinic, discusses the criteria for liver transplantation in patients with hepatocellular carcinoma (HCC).

Numerous changes in liver transplantation criteria have taken place over several years, both overall and specific to HCC, according to Heimbach. These changes began in 2018 when standard downstaging criteria were adopted. Previously, patients who were outside of standard Milan criteria had to go through an appeal process in order to undergo transplant, but this is no longer the case, says Heimbach. Patients who are outside of the Milan criteria but have been successfully downstaged can now go through a standard process for transplant, she explains.

Additionally, another policy change was adopted for patients with exceptions in HCC, which comprises approximately 70% of the exceptions. 

Thus far, a standard patient with HCC who is meeting transplant criteria and is going to have an exception previously were given a score that increased every 3 months, she says. Since May 2020, if a patient is given a score that has started just below the median where they were offered transplant, their score stays there, Heimbach says. While it starts higher than it used to, it doesn't go up, Heimbach concludes.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.